(MedPage Today) — As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works best has gained importance.
The anti-immunoglobulin E (IgE) antibody omalizumab (Xolair) was first out…
Source link : https://www.medpagetoday.com/spotlight/acaai-csu/118523
Author :
Publish date : 2025-11-14 15:59:00
Copyright for syndicated content belongs to the linked Source.
